GenMark Diagnostics, Inc (NASDAQ:GNMK) insider Hany Massarany sold 8,047 shares of GenMark Diagnostics stock in a transaction dated Tuesday, November 20th. The shares were sold at an average price of $4.84, for a total value of $38,947.48. Following the transaction, the insider now directly owns 672,883 shares in the company, valued at $3,256,753.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Hany Massarany also recently made the following trade(s):
- On Tuesday, November 27th, Hany Massarany sold 5,884 shares of GenMark Diagnostics stock. The stock was sold at an average price of $5.08, for a total value of $29,890.72.
- On Monday, November 5th, Hany Massarany sold 1,561 shares of GenMark Diagnostics stock. The stock was sold at an average price of $4.85, for a total value of $7,570.85.
GenMark Diagnostics stock traded down $0.01 during mid-day trading on Monday, hitting $5.21. The company’s stock had a trading volume of 226,700 shares, compared to its average volume of 341,973. The company has a market capitalization of $291.53 million, a PE ratio of -4.35 and a beta of 1.27. The company has a quick ratio of 3.10, a current ratio of 3.75 and a debt-to-equity ratio of 0.69. GenMark Diagnostics, Inc has a one year low of $3.98 and a one year high of $8.81.
A number of analysts have issued reports on the company. BidaskClub downgraded GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 17th. Finally, ValuEngine raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $10.33.
Several hedge funds have recently modified their holdings of GNMK. Millennium Management LLC lifted its holdings in shares of GenMark Diagnostics by 1,118.6% in the 2nd quarter. Millennium Management LLC now owns 741,752 shares of the medical equipment provider’s stock worth $4,732,000 after buying an additional 680,882 shares during the period. BlackRock Inc. lifted its holdings in shares of GenMark Diagnostics by 7.5% in the 3rd quarter. BlackRock Inc. now owns 3,609,795 shares of the medical equipment provider’s stock worth $26,532,000 after buying an additional 251,078 shares during the period. Bellevue Group AG lifted its holdings in shares of GenMark Diagnostics by 12.9% in the 3rd quarter. Bellevue Group AG now owns 1,339,502 shares of the medical equipment provider’s stock worth $9,845,000 after buying an additional 153,000 shares during the period. Bradley Foster & Sargent Inc. CT purchased a new stake in shares of GenMark Diagnostics in the 2nd quarter worth $651,000. Finally, Private Wealth Partners LLC lifted its holdings in shares of GenMark Diagnostics by 23.3% in the 2nd quarter. Private Wealth Partners LLC now owns 370,000 shares of the medical equipment provider’s stock worth $2,361,000 after buying an additional 70,000 shares during the period. Institutional investors and hedge funds own 97.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “GenMark Diagnostics, Inc (NASDAQ:GNMK) Insider Sells $38,947.48 in Stock” was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2018/12/03/insider-selling-genmark-diagnostics-inc-gnmk-insider-sells-8047-shares-of-stock.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Featured Story: Why do corrections happen?
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.